SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

Among adults with type 2 diabetes, SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases compared with sulfonylureas.

Patients with asthma and T2 diabetes using SGLT2 inhibitors have a significantly decreased mortality risk within 30 days of an asthma exacerbation.

Please provide your email address to receive an email when new articles are posted on . Most patients who qualify for an SGLT2 inhibitor are not prescribed one. Prescription rates for those with a ...

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...

Please provide your email address to receive an email when new articles are posted on . SGLT2 and GLP-1 agents were linked to lower risk of kidney-related outcomes for adults with type 2 diabetes and ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

STOCKHOLM -- The sodium glucose co-transporter 2 (SGLT2) class of diabetes medications may offer more protection against diabetic retinopathy as compared with other hypoglycemic agents, an analysis of ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...